Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin. Results from the Phase 2 study were published in Blood Cancer Journal. Among 37 patients…